Registry of Lobbyists
Version 1 of 2 (2003-01-24 to 2004-01-28) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.
| Corporation: |
GLAXOSMITHKLINE
CONSTITUTION SQUARE, 360 ALBERT STREET, SUITE 1110 OTTAWA, ON K1R 7X7 Canada |
| Telephone number: | 613-569-6619 |
| Fax number: | 613-569-6816 |
| Responsible officer name and position during the period of this registration: | BLAIR DICKERSON, EXTERNAL AFFAIRS |
| Description of activities: | DESCRIPTION OF ORGANIZATION/DESCRIPTION DE L'ORGANISATIONGLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. ON DECEMBER 27TH, 2000 GLAXO WELLCOME PLC AMALGAMATED WITH SMITHKLINE BEECHAM PLC TO CREATE GLAXOSMITHKLINE PLC ONE OF THE WORLD'S LARGEST PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN ADDITION, GLAXOSMITHKLINE HAS REGIONAL BUSINESS OFFICES LOCATED IN HALIFAX, OTTAWA, WINNIPEG, CALGARY AND VANCOUVER PLUS DISTRIBUTION CENTRES LOCATED IN MONCTON, TORONTO AND CALGARY. IN TOTAL GLAXOSMITHKLINE EMPLOYEES APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY.GLAXOSMITHKLINE IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. IN ADDITION, GLAXOSMITHKLINE ANNUALLY CONDUCTS MORE THAN 200 CLINICAL STUDIES IN CANADA, INVOLVING SOME 40,000 PATIENTS AND 3,000 PHYSICANS. THESE PROGRAMS REPRESENT 10 PER CENT OF THE COMPANY'S WORLDWIDE CLINICAL TRIALS PROGRAM. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY. GLAXOSMITHKLINE HAS SECURED WORLDWIDE PRODUCTION MANDATES FOR ITS FACILITY IN MISSSISSAUGA TO MANUFACTURE MEPRON, TO TREAT PNEUMONIA COMMON IN AIDS PATIENTS, AND MALARONE, TO TREAT MALARIA. |
| The client is a subsidiary of the following parent companies: |
GLAXO WELLCOME PLC
LANDSDOWN HOUSE, BERKELEY SQUARE LONDON W1XGBP United Kingdom |
| Coalition | The corporation is not a member of a coalition. |
| Subsidiary: | The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking. |
| Other direct interests | The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking. |
| Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? | No |
| Federal departments or organizations which have been or will be communicated with during the course of the undertaking: | Aboriginal Affairs and Northern Development Canada, Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Environment Canada, Federal Environmental Assessment Review Office (FEARO), Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Patented Medicine Prices Review Board (PMPRB), Social Sciences and Humanities Research Council (SSHRC), Treasury Board Of Canada Secretariat (TBS), Western Economic Diversification Canada (WD) |
|
Communication techniques that have been used or are expected to be used in the course of the undertaking:
|
Grass-roots communication, Informal communications |
| Subject Matter: Areas of Concern: | Consumer Issues, Education, Employment and Training, Environment, Health, Industry, Intellectual Property, International Trade, Regional Development, Science and Technology, Taxation and Finance |
| Subject Matter: Particulars: | ANY LEGISLATIVE PROPOSALS, POLICIES OR PAPERS, BILLS OR RESOLUTIONS, OR REGULATIONS THAT WOULD IMPACT THE BRAND NAME PHARMACEUTICAL INDUSTRY OR THE REVIEW OF ANY DRUG PATENT LEGISLATION (SUCH AS BILL C-91); PHARMACARE OR HOME CARE PROGRAMS; DRUG APPROVALS POLICIES AND PROCESSES. |